CUSIP: 13739U104
Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,199,743
-
Share change
-
+664,479
-
Total reported value
-
$12,639,000
-
Price per share
-
$3.95
-
Number of holders
-
28
-
Value change
-
+$2,609,974
-
Number of buys
-
15
-
Number of sells
-
15
Quarterly Holders Quick Answers
What is CUSIP 13739U104?
CUSIP 13739U104 identifies CGIX - CANCER GENETICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2017
-
Previous quarter:
Q1 2017
Recent filing periods for CUSIP 13739U104:
Institutional Holders of CANCER GENETICS INC - COM (CGIX) as of Q2 2017
As of 30 Jun 2017,
CANCER GENETICS INC - COM (CGIX) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,199,743 shares.
The largest 10 holders included
PERKINS CAPITAL MANAGEMENT INC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, Fairbanks Capital Management, Inc., UBS Group AG, GRANAHAN INVESTMENT MANAGEMENT INC/MA, THOMPSON DAVIS & CO., INC., EAM Investors, LLC, GEODE CAPITAL MANAGEMENT, LLC, and DIKER MANAGEMENT LLC.
This page lists
28
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.